























American Society for Pharmacology and Experimental Therapeutics, 32,821–827.

- [107] W. Liu , S. S. Baker , J. Trinidad , A. L. Burlingame , R. D. Baker , J. G. Forte , L. P. Virtuoso , N. K. Egilmez ,and L. Zhu, (2013). Inhibition of lysosomal enzyme activities by proton pump inhibitors. *J Gastroenterol.*, 48(12):1343-1352.
- [108] T. Lynch, and A. Price, (2007). The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects. *American Family Physician*, 76(3), 391-396.
- [109] G. R. Wilkinson, (2005). Drug metabolism and variability among patients in drug response. *N Engl J Med*, 352, 2211-2221.
- [110] J. P. Villeneuve, and V. Pichette, (2004). Cytochrome P450 and liver diseases. *Curr Drug Metab*, 5(3), 273-282.
- [111] T. Hussain , O. S. Al-Attas , N. M. Al-Daghri , A. A. Mohammed , E. De Rosas , S. Ibrahim , B . Vinodson , M. G. Ansari , K. I. El-Din, (2014). Induction of CYP1A1, CYP1A2, CYP1B1, increased oxidative stress and inflammation in the lung and liver tissues of rats exposed to incense smoke. *Mol Cell Biochem.*, 391(1-2),127-136.
- [112] U. Yasar, C. Forslund-Bergengren, G. Tybring, P. Dorado, A. Llerena, F. Sjoqvist, et al., (2002). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the *CYP2C9* genotype. *Clin Pharmacol Ther*, 71, 89-98.